» Articles » PMID: 17938288

Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-cell Mediated Injury in the Heart

Overview
Journal Circulation
Date 2007 Oct 17
PMID 17938288
Citations 160
Authors
Affiliations
Soon will be listed here.
Abstract

Background: PD-L1 and PD-L2 are ligands for the inhibitory receptor programmed death-1 (PD-1), which is an important regulator of immune responses. PD-L1 is induced on cardiac endothelial cells under inflammatory conditions, but little is known about its role in regulating immune injury in the heart.

Methods And Results: Cytotoxic T-lymphocyte-mediated myocarditis was induced in mice, and the influence of PD-L1 signaling was studied with PD-L1/L2-deficient mice and blocking antibodies. During cytotoxic T-lymphocyte-induced myocarditis, the upregulation of PD-L1 on cardiac endothelia was dependent on T-cell-derived interferon-gamma, and blocking of interferon-gamma signaling worsened disease. Genetic deletion of both PD-1 ligands [PD-L1/2(-/-)], as well as treatment with PD-L1 blocking antibody, transformed transient myocarditis to lethal disease, in association with widespread polymorphonuclear leukocyte-rich microabscesses but without change in cytotoxic T-lymphocyte recruitment. PD-L1/2(-/-) mice reconstituted with bone marrow from wild-type mice remained susceptible to severe disease, which demonstrates that PD-L1 on non-bone marrow-derived cells confers the protective effect. Finally, depletion of polymorphonuclear leukocytes reversed the enhanced susceptibility to lethal myocarditis attributable to PD-L1 deficiency.

Conclusions: Myocardial PD-L1, mainly localized on endothelium, is critical for control of immune-mediated cardiac injury and polymorphonuclear leukocyte inflammation.

Citing Articles

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model.

Schoenherr C, Pietzsch S, Barca C, Muller F, Bahr F, Kasten M Front Mol Med. 2025; 4():1487526.

PMID: 39834851 PMC: 11743445. DOI: 10.3389/fmmed.2024.1487526.


Changes in tumor and cardiac metabolism upon immune checkpoint.

Leven A, Wagner N, Nienaber S, Messiha D, Tasdogan A, Ugurel S Basic Res Cardiol. 2024; 120(1):133-152.

PMID: 39658699 PMC: 11790718. DOI: 10.1007/s00395-024-01092-8.


Special immune-related adverse events and subsequent photodynamic therapy in tislelizumab treatment for esophageal cancer: a case report.

Li L, Bian L, Kou N, Yuan Y, Zou H Front Immunol. 2024; 15:1497259.

PMID: 39654898 PMC: 11625816. DOI: 10.3389/fimmu.2024.1497259.


Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.

Gao H, Chen Z, Yao Y, He Y, Hu X Front Oncol. 2024; 14:1453090.

PMID: 39634266 PMC: 11614734. DOI: 10.3389/fonc.2024.1453090.


Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).

Abulizi A, Yan G, Xu Q, Muhetaer R, Wu S, Abudukelimu K Sci Rep. 2024; 14(1):25919.

PMID: 39472591 PMC: 11522629. DOI: 10.1038/s41598-024-75099-5.